Prospecta is a new nootropic medication that normalizes brain activity in people with cognitive disorders of various origins, including in the wake of acute cerebral circulation disorders.
Flat-cylindrical tablets, with a risk and a chamfer, from white to almost white. On the flat side with a risk, the inscription MATERIA MEDICA is applied, on the other flat side, the inscription PROSPEKTA is applied.
Prospecta® is indicated for use in adults for the treatment of the following disorders:
- cognitive disorders of various origins, including those after acute cerebrovascular accidents.
- asthenic conditions in the post-infection period, including after a coronavirus infection (COVID-19).
Prospecta® is indicated for use in children aged 7 years and over for the treatment of Attention Deficit Hyperactivity Disorder.
Cognitive disorders of various origins, including those after acute cerebrovascular accidents:
Take 2 tablets 2 times a day. The course of treatment is 6 months; if necessary, the course of treatment can be repeated after 1-2 months.
Postinfectious asthenic conditions:
Take 1 tablet 2 times a day. The course of treatment is 1 month; if necessary, the course of treatment can be repeated after 1-2 months.
Attention Deficit Hyperactivity Disorder:
Take 1 tablet 2 times a day (at about the same time). The course of treatment is 8 weeks; if necessary, the course of treatment can be repeated.
